The global market for Investigational New Drug CDMO was valued at US$ 5013 million in the year 2024 and is projected to reach a revised size of US$ 7743 million by 2031, growing at a CAGR of 6.5% during the forecast period.

Investigational New Drug CDMO Market

Investigational New Drug CDMO refers to a Contract Development and Manufacturing Organization (CDMO) that specializes in the development and production of investigational new drugs (INDs). INDs are drugs that are being tested for their safety and efficacy in clinical trials before they receive regulatory approval for general use. An Investigational New Drug CDMO provides services including formulation development, process optimization, scale-up, and manufacturing of INDs to support the drug development process. These organizations play a crucial role in helping pharmaceutical companies bring new drugs from the research phase through to clinical trials.

North American market for Investigational New Drug CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Investigational New Drug CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Investigational New Drug CDMO in Pharmaceutical Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Investigational New Drug CDMO include Catalent, Inc., Lonza, Recipharm AB, Siegfried Holding AG, Patheon Inc., Covance, IQVIA Holdings Inc., Cambrex Corporation, Charles River Laboratories International, Inc., Syneous Health, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Investigational New Drug CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Investigational New Drug CDMO.

The Investigational New Drug CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Investigational New Drug CDMO market comprehensively. Regional market sizes, concerning products by Type, by End User, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Investigational New Drug CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by End User, and by regions.

Market Segmentation

Scope of Investigational New Drug CDMO Market Report

Report Metric	Details
Report Name	Investigational New Drug CDMO Market
Accounted market size in year	US$ 5013 million
Forecasted market size in 2031	US$ 7743 million
CAGR	6.5%
Base Year	year
Forecasted years	2026 - 2031
Segment by Type	Small Molecule Large Molecule
Segment by End User	Pharmaceutical Companies Biotech Companies Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Catalent, Inc., Lonza, Recipharm AB, Siegfried Holding AG, Patheon Inc., Covance, IQVIA Holdings Inc., Cambrex Corporation, Charles River Laboratories International, Inc., Syneous Health
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by End User, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Investigational New Drug CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by End User, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Investigational New Drug CDMO Market growing?

Ans: The Investigational New Drug CDMO Market witnessing a CAGR of 6.5% during the forecast period 2026-2031.

What is the Investigational New Drug CDMO Market size in 2031?

Ans: The Investigational New Drug CDMO Market size in 2031 will be US$ 7743 million.

Who are the main players in the Investigational New Drug CDMO Market report?

Ans: The main players in the Investigational New Drug CDMO Market are Catalent, Inc., Lonza, Recipharm AB, Siegfried Holding AG, Patheon Inc., Covance, IQVIA Holdings Inc., Cambrex Corporation, Charles River Laboratories International, Inc., Syneous Health

What are the Type segmentation covered in the Investigational New Drug CDMO Market report?

Ans: The Types covered in the Investigational New Drug CDMO Market report are Small Molecule, Large Molecule

What are the End User segmentation covered in the Investigational New Drug CDMO Market report?

Ans: The End users covered in the Investigational New Drug CDMO Market report are Pharmaceutical Companies, Biotech Companies, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Investigational New Drug CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Small Molecule

1.2.3 Large Molecule

1.3 Market by End User

1.3.1 Global Investigational New Drug CDMO Market Growth by End User: 2020 VS 2024 VS 2031

1.3.2 Pharmaceutical Companies

1.3.3 Biotech Companies

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Investigational New Drug CDMO Market Perspective (2020-2031)

2.2 Global Investigational New Drug CDMO Growth Trends by Region

2.2.1 Global Investigational New Drug CDMO Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Investigational New Drug CDMO Historic Market Size by Region (2020-2025)

2.2.3 Investigational New Drug CDMO Forecasted Market Size by Region (2026-2031)

2.3 Investigational New Drug CDMO Market Dynamics

2.3.1 Investigational New Drug CDMO Industry Trends

2.3.2 Investigational New Drug CDMO Market Drivers

2.3.3 Investigational New Drug CDMO Market Challenges

2.3.4 Investigational New Drug CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Investigational New Drug CDMO Players by Revenue

3.1.1 Global Top Investigational New Drug CDMO Players by Revenue (2020-2025)

3.1.2 Global Investigational New Drug CDMO Revenue Market Share by Players (2020-2025)

3.2 Global Investigational New Drug CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Investigational New Drug CDMO Revenue

3.4 Global Investigational New Drug CDMO Market Concentration Ratio

3.4.1 Global Investigational New Drug CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Investigational New Drug CDMO Revenue in 2024

3.5 Global Key Players of Investigational New Drug CDMO Head office and Area Served

3.6 Global Key Players of Investigational New Drug CDMO, Product and Application

3.7 Global Key Players of Investigational New Drug CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Investigational New Drug CDMO Breakdown Data by Type

4.1 Global Investigational New Drug CDMO Historic Market Size by Type (2020-2025)

4.2 Global Investigational New Drug CDMO Forecasted Market Size by Type (2026-2031)

5 Investigational New Drug CDMO Breakdown Data by End User

5.1 Global Investigational New Drug CDMO Historic Market Size by End User (2020-2025)

5.2 Global Investigational New Drug CDMO Forecasted Market Size by End User (2026-2031)

6 North America

6.1 North America Investigational New Drug CDMO Market Size (2020-2031)

6.2 North America Investigational New Drug CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Investigational New Drug CDMO Market Size by Country (2020-2025)

6.4 North America Investigational New Drug CDMO Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Investigational New Drug CDMO Market Size (2020-2031)

7.2 Europe Investigational New Drug CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Investigational New Drug CDMO Market Size by Country (2020-2025)

7.4 Europe Investigational New Drug CDMO Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Investigational New Drug CDMO Market Size (2020-2031)

8.2 Asia-Pacific Investigational New Drug CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Investigational New Drug CDMO Market Size by Region (2020-2025)

8.4 Asia-Pacific Investigational New Drug CDMO Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Investigational New Drug CDMO Market Size (2020-2031)

9.2 Latin America Investigational New Drug CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Investigational New Drug CDMO Market Size by Country (2020-2025)

9.4 Latin America Investigational New Drug CDMO Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Investigational New Drug CDMO Market Size (2020-2031)

10.2 Middle East & Africa Investigational New Drug CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Investigational New Drug CDMO Market Size by Country (2020-2025)

10.4 Middle East & Africa Investigational New Drug CDMO Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Catalent, Inc.

11.1.1 Catalent, Inc. Company Details

11.1.2 Catalent, Inc. Business Overview

11.1.3 Catalent, Inc. Investigational New Drug CDMO Introduction

11.1.4 Catalent, Inc. Revenue in Investigational New Drug CDMO Business (2020-2025)

11.1.5 Catalent, Inc. Recent Development

11.2 Lonza

11.2.1 Lonza Company Details

11.2.2 Lonza Business Overview

11.2.3 Lonza Investigational New Drug CDMO Introduction

11.2.4 Lonza Revenue in Investigational New Drug CDMO Business (2020-2025)

11.2.5 Lonza Recent Development

11.3 Recipharm AB

11.3.1 Recipharm AB Company Details

11.3.2 Recipharm AB Business Overview

11.3.3 Recipharm AB Investigational New Drug CDMO Introduction

11.3.4 Recipharm AB Revenue in Investigational New Drug CDMO Business (2020-2025)

11.3.5 Recipharm AB Recent Development

11.4 Siegfried Holding AG

11.4.1 Siegfried Holding AG Company Details

11.4.2 Siegfried Holding AG Business Overview

11.4.3 Siegfried Holding AG Investigational New Drug CDMO Introduction

11.4.4 Siegfried Holding AG Revenue in Investigational New Drug CDMO Business (2020-2025)

11.4.5 Siegfried Holding AG Recent Development

11.5 Patheon Inc.

11.5.1 Patheon Inc. Company Details

11.5.2 Patheon Inc. Business Overview

11.5.3 Patheon Inc. Investigational New Drug CDMO Introduction

11.5.4 Patheon Inc. Revenue in Investigational New Drug CDMO Business (2020-2025)

11.5.5 Patheon Inc. Recent Development

11.6 Covance

11.6.1 Covance Company Details

11.6.2 Covance Business Overview

11.6.3 Covance Investigational New Drug CDMO Introduction

11.6.4 Covance Revenue in Investigational New Drug CDMO Business (2020-2025)

11.6.5 Covance Recent Development

11.7 IQVIA Holdings Inc.

11.7.1 IQVIA Holdings Inc. Company Details

11.7.2 IQVIA Holdings Inc. Business Overview

11.7.3 IQVIA Holdings Inc. Investigational New Drug CDMO Introduction

11.7.4 IQVIA Holdings Inc. Revenue in Investigational New Drug CDMO Business (2020-2025)

11.7.5 IQVIA Holdings Inc. Recent Development

11.8 Cambrex Corporation

11.8.1 Cambrex Corporation Company Details

11.8.2 Cambrex Corporation Business Overview

11.8.3 Cambrex Corporation Investigational New Drug CDMO Introduction

11.8.4 Cambrex Corporation Revenue in Investigational New Drug CDMO Business (2020-2025)

11.8.5 Cambrex Corporation Recent Development

11.9 Charles River Laboratories International, Inc.

11.9.1 Charles River Laboratories International, Inc. Company Details

11.9.2 Charles River Laboratories International, Inc. Business Overview

11.9.3 Charles River Laboratories International, Inc. Investigational New Drug CDMO Introduction

11.9.4 Charles River Laboratories International, Inc. Revenue in Investigational New Drug CDMO Business (2020-2025)

11.9.5 Charles River Laboratories International, Inc. Recent Development

11.10 Syneous Health

11.10.1 Syneous Health Company Details

11.10.2 Syneous Health Business Overview

11.10.3 Syneous Health Investigational New Drug CDMO Introduction

11.10.4 Syneous Health Revenue in Investigational New Drug CDMO Business (2020-2025)

11.10.5 Syneous Health Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Charles River Laboratories International, Inc.

Syneous Health

List of Tables

Table 1. Global Investigational New Drug CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Small Molecule

Table 3. Key Players of Large Molecule

Table 4. Global Investigational New Drug CDMO Market Size Growth by End User (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Investigational New Drug CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Investigational New Drug CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Investigational New Drug CDMO Market Share by Region (2020-2025)

Table 8. Global Investigational New Drug CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Investigational New Drug CDMO Market Share by Region (2026-2031)

Table 10. Investigational New Drug CDMO Market Trends

Table 11. Investigational New Drug CDMO Market Drivers

Table 12. Investigational New Drug CDMO Market Challenges

Table 13. Investigational New Drug CDMO Market Restraints

Table 14. Global Investigational New Drug CDMO Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Investigational New Drug CDMO Market Share by Players (2020-2025)

Table 16. Global Top Investigational New Drug CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Investigational New Drug CDMO as of 2024)

Table 17. Ranking of Global Top Investigational New Drug CDMO Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Investigational New Drug CDMO Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Investigational New Drug CDMO, Headquarters and Area Served

Table 20. Global Key Players of Investigational New Drug CDMO, Product and Application

Table 21. Global Key Players of Investigational New Drug CDMO, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Investigational New Drug CDMO Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Investigational New Drug CDMO Revenue Market Share by Type (2020-2025)

Table 25. Global Investigational New Drug CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Investigational New Drug CDMO Revenue Market Share by Type (2026-2031)

Table 27. Global Investigational New Drug CDMO Market Size by End User (2020-2025) & (US$ Million)

Table 28. Global Investigational New Drug CDMO Revenue Market Share by End User (2020-2025)

Table 29. Global Investigational New Drug CDMO Forecasted Market Size by End User (2026-2031) & (US$ Million)

Table 30. Global Investigational New Drug CDMO Revenue Market Share by End User (2026-2031)

Table 31. North America Investigational New Drug CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Investigational New Drug CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Investigational New Drug CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Investigational New Drug CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Investigational New Drug CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Investigational New Drug CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Investigational New Drug CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Investigational New Drug CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Investigational New Drug CDMO Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Investigational New Drug CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Investigational New Drug CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Investigational New Drug CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Investigational New Drug CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Investigational New Drug CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Investigational New Drug CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 46. Catalent, Inc. Company Details

Table 47. Catalent, Inc. Business Overview

Table 48. Catalent, Inc. Investigational New Drug CDMO Product

Table 49. Catalent, Inc. Revenue in Investigational New Drug CDMO Business (2020-2025) & (US$ Million)

Table 50. Catalent, Inc. Recent Development

Table 51. Lonza Company Details

Table 52. Lonza Business Overview

Table 53. Lonza Investigational New Drug CDMO Product

Table 54. Lonza Revenue in Investigational New Drug CDMO Business (2020-2025) & (US$ Million)

Table 55. Lonza Recent Development

Table 56. Recipharm AB Company Details

Table 57. Recipharm AB Business Overview

Table 58. Recipharm AB Investigational New Drug CDMO Product

Table 59. Recipharm AB Revenue in Investigational New Drug CDMO Business (2020-2025) & (US$ Million)

Table 60. Recipharm AB Recent Development

Table 61. Siegfried Holding AG Company Details

Table 62. Siegfried Holding AG Business Overview

Table 63. Siegfried Holding AG Investigational New Drug CDMO Product

Table 64. Siegfried Holding AG Revenue in Investigational New Drug CDMO Business (2020-2025) & (US$ Million)

Table 65. Siegfried Holding AG Recent Development

Table 66. Patheon Inc. Company Details

Table 67. Patheon Inc. Business Overview

Table 68. Patheon Inc. Investigational New Drug CDMO Product

Table 69. Patheon Inc. Revenue in Investigational New Drug CDMO Business (2020-2025) & (US$ Million)

Table 70. Patheon Inc. Recent Development

Table 71. Covance Company Details

Table 72. Covance Business Overview

Table 73. Covance Investigational New Drug CDMO Product

Table 74. Covance Revenue in Investigational New Drug CDMO Business (2020-2025) & (US$ Million)

Table 75. Covance Recent Development

Table 76. IQVIA Holdings Inc. Company Details

Table 77. IQVIA Holdings Inc. Business Overview

Table 78. IQVIA Holdings Inc. Investigational New Drug CDMO Product

Table 79. IQVIA Holdings Inc. Revenue in Investigational New Drug CDMO Business (2020-2025) & (US$ Million)

Table 80. IQVIA Holdings Inc. Recent Development

Table 81. Cambrex Corporation Company Details

Table 82. Cambrex Corporation Business Overview

Table 83. Cambrex Corporation Investigational New Drug CDMO Product

Table 84. Cambrex Corporation Revenue in Investigational New Drug CDMO Business (2020-2025) & (US$ Million)

Table 85. Cambrex Corporation Recent Development

Table 86. Charles River Laboratories International, Inc. Company Details

Table 87. Charles River Laboratories International, Inc. Business Overview

Table 88. Charles River Laboratories International, Inc. Investigational New Drug CDMO Product

Table 89. Charles River Laboratories International, Inc. Revenue in Investigational New Drug CDMO Business (2020-2025) & (US$ Million)

Table 90. Charles River Laboratories International, Inc. Recent Development

Table 91. Syneous Health Company Details

Table 92. Syneous Health Business Overview

Table 93. Syneous Health Investigational New Drug CDMO Product

Table 94. Syneous Health Revenue in Investigational New Drug CDMO Business (2020-2025) & (US$ Million)

Table 95. Syneous Health Recent Development

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

Table 99. Authors List of This Report

List of Figures

Figure 1. Investigational New Drug CDMO Picture

Figure 2. Global Investigational New Drug CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Investigational New Drug CDMO Market Share by Type: 2024 VS 2031

Figure 4. Small Molecule Features

Figure 5. Large Molecule Features

Figure 6. Global Investigational New Drug CDMO Market Size by End User (2020-2031) & (US$ Million)

Figure 7. Global Investigational New Drug CDMO Market Share by End User: 2024 VS 2031

Figure 8. Pharmaceutical Companies Case Studies

Figure 9. Biotech Companies Case Studies

Figure 10. Others Case Studies

Figure 11. Investigational New Drug CDMO Report Years Considered

Figure 12. Global Investigational New Drug CDMO Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Investigational New Drug CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Investigational New Drug CDMO Market Share by Region: 2024 VS 2031

Figure 15. Global Investigational New Drug CDMO Market Share by Players in 2024

Figure 16. Global Top Investigational New Drug CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Investigational New Drug CDMO as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Investigational New Drug CDMO Revenue in 2024

Figure 18. North America Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Investigational New Drug CDMO Market Share by Country (2020-2031)

Figure 20. United States Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Investigational New Drug CDMO Market Share by Country (2020-2031)

Figure 24. Germany Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Investigational New Drug CDMO Market Share by Region (2020-2031)

Figure 32. China Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Investigational New Drug CDMO Market Share by Country (2020-2031)

Figure 40. Mexico Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Investigational New Drug CDMO Market Share by Country (2020-2031)

Figure 44. Turkey Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Investigational New Drug CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Catalent, Inc. Revenue Growth Rate in Investigational New Drug CDMO Business (2020-2025)

Figure 48. Lonza Revenue Growth Rate in Investigational New Drug CDMO Business (2020-2025)

Figure 49. Recipharm AB Revenue Growth Rate in Investigational New Drug CDMO Business (2020-2025)

Figure 50. Siegfried Holding AG Revenue Growth Rate in Investigational New Drug CDMO Business (2020-2025)

Figure 51. Patheon Inc. Revenue Growth Rate in Investigational New Drug CDMO Business (2020-2025)

Figure 52. Covance Revenue Growth Rate in Investigational New Drug CDMO Business (2020-2025)

Figure 53. IQVIA Holdings Inc. Revenue Growth Rate in Investigational New Drug CDMO Business (2020-2025)

Figure 54. Cambrex Corporation Revenue Growth Rate in Investigational New Drug CDMO Business (2020-2025)

Figure 55. Charles River Laboratories International, Inc. Revenue Growth Rate in Investigational New Drug CDMO Business (2020-2025)

Figure 56. Syneous Health Revenue Growth Rate in Investigational New Drug CDMO Business (2020-2025)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions